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Summary Angiogenin is a 14kD protein, initially isolated as a tumour-cell secreted product but subsequently
found to be a normal constituent of human plasma. It is a potent inducer of blood vessel formation on the
chorioallantoic membrane of the chick embryo. Chemical characterization of the protein reveals a remarkable
homology to the pancreatic ribonuclease family and has led to the identification of a unique ribonucleolytic
activity for angiogenin. It is a particularly potent inhibitor of in vitro protein synthesis. Treatment with
placental ribonuclease inhibitor abolishes the biological and enzymatic activities of angiogenin, an effect with
important mechanistic, physiological and pharmacologic implications.
Angiogenin is a 14,000 molecular weight protein, first
isolated from tumour cell conditioned medium (Fett et al.,
1985), which induces neovascularization in the chick chorio-
allantoic membrane. Its primary sequence is 35% iden-
tical to that of human pancreatic ribonuclease (Strydom
et al., 1985), and, indeed, it exhibits ribonucleolytic activity,
albeit markedly different from that of the pancreatic enzyme
(Shapiro et al., 1986).
The proliferation of blood vessels in the vicinity of solid
tumours was first described over a century ago and has been
viewed as critical for tumour growth. This requirement led
to the concept of tumour-induced angiogenesis whereby
tumour cells secrete a substance(s) that promotes the
proliferation of new blood vessels (Folkman & Cotran,
1976). Much attention has been directed toward such a
substance since it might serve as a therapeutic target to
control neoplastic growth (Folkman & Klagsbrun, 1987).
Efforts of identify a molecular species capable of inducing
the growth of new blood vessels were also stimulated by the
more general issue of how organs are induced in the first
place. The organizer concept, initially expounded by
Spemann and coworkers (Spemann & Mangold, 1924) and
by Needham (1936) amongst others, suggested that specific
molecules are involved in the initiation of organ
differentiation. The availability of assay methods for
measuring blood vessel formation, while imprecise and
problematic, provided the final impetus to undertake this
investigation.
Isolation ofangiogenin
The initial strategy for attempting to purify angiogenin was
based on the supposition that it would be secreted by
tumour cells and, hence, be present in tumour cell-
conditioned medium. Typically, however, foetal calf serum is
added to such medium to provide a source of growth factors
for the cells but this simultaneously contributes a sizeable
background of contaminating proteins. To overcome this
problem a procedure was therefore employed in which the
cells were temporarily transferred from growth medium to
phosphate-buffered saline (PBS) into which they were
allowed to secrete proteins for several hours. Indeed
angiogenin activity could be detected in the PBS solution,
seemingly confirming its secretory origin, but it eventually
became apparent that this approach would never provide
sufflicient material for compositional let alone sequence
analysis. Indeed, it was never clear if the presence of this
activity was due to secretion or cell lysis, an unavoidable
accompaniment of the procedure. Therefore conditions were
sought where tumour cells could be grown in the absence of
foetal calf serum. Eventually it was found that tumour cells
could be maintained in serum-free medium supplemented
with 5mM glutamine (Alderman et al., 1985). Although they
do not proliferate under these conditions, the cells
continuously secrete proteins into the medium for periods of
up to several months. By scaling up this method using cell
factories, multilitre quantities of medium containing
microgram amounts of angiogenin could be obtained on a
weekly basis (Table I). Tedious stockpiling eventually
produced enough of the pure material for detailed structural
characterization. It remained obvious, however, that an even
more abundant source would be required if mechanistic
studies and therapeutic applications were to be pursued.
Since the gene and cDNA for angiogenin had been
isolated from normal human liver (Kurachi et al., 1985) it
seemed reasonable to expect that the protein might be
present in normal human tissues. Moreover, it was known
from the gene sequence that the primary translation product
contains a signal peptide, consistent with angiogenin being a
secreted protein. Consequently, normal human plasma was
examined for the presence of angiogenin since it could serve
as a suitable alternative source owing to its ready avail-
ability. Remarkably, both plasma and serum were found to
contain a protein that is physically and functionally identical
with angiogenin and which by radioimmunoassay is present
at a concentration of - 400 igl-1, substantially greater than
the 5 igl-1 found in HT-29 cell-conditioned medium
(Shapiro et al., 1987a). A two-step procedure involving
CM52 and Mono-S cation-exchange chromatography
produces a homogeneous protein from human plasma in
-25% yield. Thus it became possible to obtain 1-2mg of
angiogenin per week, instead of the year or more required
previously (Table I).
Despite this major breakthrough, it seemed likely that
production, in addition to being quite costly, might still be
inadequate for the many applications contemplated.
Therefore, the possibility of using a mammalian cell
expression system for larger scale production was examined.
Baby hamster kidney cells were transformed with DNA
sequences derived from the gene for angiogenin, and protein
Table I Purification of angiogenin from HT-29 conditioned
medium and from normal human plasma
Protein, mg Purification
HT-29 conditioned mediuma
Medium, 10 litres 16 1
Acid, freeze-thaw 6.3 2.5
CM-Cellulose, bound 2.3 7.0
RP-HPLC, pool A 0.005 3,200
Normal human plasmab
Plasma, 10 litres 590,000 1
CM-Cellulose, bound, 19.7 30,000
Mono S HPLC 0.75 787,000
aFett et al. (1985). bShapiro et al. (1987a).
Correspondence: B.L. Vallee.
*Presented, by invitation, at the BACR/CRC/ICRF Symposium in
'Growth factors', London, December 1987.
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expression was placed under the transcriptional control of
the zinc- and cadmium-inducible mouse metallothionein 1
promoter. Recombinant angiogenin was then isolated from
the BHK cell conditioned medium by a modification of
earlier procedures that included an additional C18 RP-
HPLC step. The product was identical to HT-29 cell
angiogenin by all criteria employed including immunological
properties, enzymatic activity toward 28S and 18S rRNA,
amino acid composition and sequence, and angiogenic
activity on the CAM. Up to 400pgl-1 medium could be
obtained in pure form. Alternative strategies to produce still
greater quantities by expressing angiogenin in bacterial
systems are currently under investigation.
Characteristics ofangiogenin
Statistical evaluation demonstrates that angiogenin displays
activity on the chick chorioallantoic membrane with as little
as 35fmol per egg. Protein isolated from HT-29 cell con-
ditioned medium, from normal human plasma or from baby
hamster kidney cells all give comparable activity.
The amino acid sequence and disulfide bond pairing of
angiogenin are now well established (Strydom et al., 1985).
The protein is a single polypeptide chain of 123 amino acids
with an isoelectric point greater than 9.5. Its N-terminus is
blocked by a pyroglutamic acid residue and its C-terminus is
proline. Three disulfide bonds link Cys 26 and 81, 39 and 92,
and 57 and 107. The complete sequence is listed in Figure 1.
Ribonuclease homology
The primary sequence of angiogenin is remarkably
homologous to that of the family of pancreatic
ribonucleases, enzymes that cleave ribonucleic acids at their
pyrimidine bases. Of the 123 amino acids in human
angiogenin 43 (35%) are identical with those at the corres-
ponding positions in human pancreatic RNase (Beintema et
al., 1984) (Table II) and another 41 either are identical with
residues in other pancreatic RNases (Blackburn & Moore,
1982; Beintema et al., 1985) or are conservative replace-
ments, constituting an overall homology of 68%.
The primary sequences of pancreatic ribonucleases from at
least 41 species are known (Blackburn & Moore, 1982;
Beintema et al., 1985), and the homology with angiogenin
holds throughout. Detailed comparisons and analogies can
be made to compare their structure, function and the
interdependence of all of these, and to examine the
evolutionary relationships of these proteins. In particular, it
will be of great interest to determine when, during the course
of evolution, angiogenin and the pancreatic RNases
diverged. Such studies would be furthered greatly by the
identification and characterization of angiogenin from other
species such as the pig, cow, and horse now underway in our
laboratory.
A preliminary three-dimensional structure of angiogenin
has been computed, based on its homology to bovine
pancreatic ribonuclease A. A standard-geometry structure of
ribonuclease was first obtained from its X-ray coordinates.
The fit of the backbone of angiogenin to that of ribonuclease
was then optimized by taking account of amino acid
deletions and by minimizing its conformational energy-plus-
a-penalty distance function constraining its backbone to that
of ribonuclease. Side-chain and backbone dihedral angles
were allowed to vary throughout the cycles of energy mini-









Figure 1 Amino acid sequence of human angiogenin (Strydom
et al., 1985).
Table II Comparison of sequence homologies
of human angiogenin and pancreatic ribo-
nuclease
Residues
Identical to human RNase 43
Identical to other RNase 25
Conservative replacements 16
Homology: 84/123 68%
distance function was removed and a low-energy structure
resembling ribonuclease was obtained (Palmer et al., 1986).
Ribonucleolytic activity ofangiogenin
Despite its high degree of homology with pancreatic ribo-
nuclease, and despite the use of very sensitive assay methods
under a variety of reaction conditions, angiogenin has not
been found to be active toward any of the conventional
substrates of that enzyme (Shapiro et al., 1986). In
particular, it does not produce detectable amounts of acid-
soluble products from high molecular weight wheat germ
RNA, poly(C), or poly(U), nor does it catalyze the
hydrolysis of cytidine- or uridine cyclic 2'3'-phosphates.
However, it is active against 28S and 18S ribosomal RNA
when tested by measuring their disappearance on agarose gel
electrophoresis. This activity differs significantly from that of
pancreatic RNase in two respects: (a) it requires 104-105 as
much angiogenin to achieve the same degree of rRNA
degradation as with ribonuclease and (b) the fragments
generated are relatively large, containing from 100 to 500
nucleotides, compared with those formed by ribonuclease.
The base-cleavage specificity ofangiogenin toward RNA has
hasbeendeterminedwithpurified5SRNAsfromSaccharomyces
cerevisiae and Escherichia coli (Rybak & Vallee, 1988). As
with ribonuclease, phosphodiester bond cleavage occurs
exclusively at the 3' side of cytidylic or uridylic acid residues,
preferably when the pyrimidine is followed by adenine.
However, angiogenin does not cleave after every pyrimidine
in the 5S RNAs and the overall pattern of cleavage is not
the same as for RNase. There is no evidence for a specific
recognition element in terms of the primary sequence of
nucleotides in the 5S RNAs. Hence, it seems likely that some
aspect of secondary structure may influence endonucleolytic
specificity. Analysis of limit digests by low voltage electro-
phoresis indicates that the regions least susceptible to
cleavage are those that derive from RNA segments where
stable, base-paired structures are presumed to form.
Inhibition ofcell-free protein synthesis
The importance of RNA secondary structure for the ribo-
nucleolytic specificity of angiogenin is further evident from
its effects on cell-free protein synthesis by the rabbit
'reticulocyte lysate system (St. Clair et al., 1987). This system
was examined to ascertain whether or not angiogenin acts
preferentially on one or another class of RNA molecules.
Remarkably, the results demonstrated that angiogenin is a
potent and, indeed, specific inhibitor of protein synthesis.
When incubated with the lysate at a concentration of 40-
60nM, angiogenin completely abolishes protein synthesis.
This inhibition is due to the ribonucleolytic activity of
angiogenin, since it is accompanied by generation of limited
cleavage products from reticulocyte RNA and the effect is
inhibited by human placental ribonuclease inhibitor.
The principal target of angiogenin in the reticulocyte
lysate is ribosomal RNA. Addition of intact ribosomes to an
angiogenin-treated lysate restores the capacity of the lysate
to support protein synthesis but addition of mRNA or
tRNA does not. However, angiogenin-treated lysosomes are
unable to restore this capacity. Moreover, the isolated
ribosomes can be resolved into 40S and 60S subunits whichHUMAN ANGIOGENIN 589
can be treated separately with angiogenin. Loss of protein
synthesis only occurs on treatment of the small subunits, not
the large subunits.
Significantly, neither the 5.8S nor 5S rRNA species are
degraded by angiogenin when they are present in the
ribosome although, as indicated above, they are susceptible
once purified. Moreover, while angiogenin, at 4060 nM,
totally abolishes protein synthesis, this concentration appears
to have little effect on 18S and 28S rRNA. This is consistent
with kinetic studies which indicate that angiogenin inhibits
either the chain elongation or termination step of protein
synthesis, not initiation. Therefore, inactivation of only a few
ribosomes would be necessary to block protein synthesis
completely (Eller et al., 1984). When 10 to 100 times more
angiogenin is added to the reticulocyte lysate the 5S and 5.8S
rRNAs are still unaffected, but now both the 28S and 18S
rRNAs undergo cleavage. The former is broken down into
low molecular weight fragments but the latter is transformed
into a 230-base product that resists further degradation.
Presumably it is this limited nucleolytic process that affects
protein synthesis since 18S RNA is a constituent of the
angiogenin-sensitive 40S ribosomal subunit.
Ribonucleolytic activity and angiogenesis
The sequence homology to the pancreatic ribonucleases, the
ribonucleolytic activity toward isolated RNA, and the potent
inhibition of cell-free protein synthesis all raise the question
of the relationship of the enzymatic activity of angiogenin to
its biological role in angiogenesis. Chemical modification of
angiogenin with bromoacetate destroys both the
ribonucleolytic and the angiogenic activity of angiogenin
virtually completely (Shapiro et al., 1987b). Similarly, as
discussed below, all of its activities are abolished on treat-
ment with human placental ribonuclease inhibitor, an effect
that may have important physiologic implications (Shapiro
& Vallee, 1987). It would appear, therefore, that the ribo-
nucleolytic potential of angiogenin is critical to the process
of angiogenesis.
Angiogenin is, of course, an extracellular protein. It is
secreted into the external medium by tumour cells growing in
culture and is present in human plasma at a concentration of
400ugl-1. Under these circumstances, however, angiogenin
is neither cytotoxic nor does it stimulate uncontrolled blood
vessel proliferation. Moreover, angiogenin has been added to
the growth medium of a wide variety of cell types and in no
instance has it been found to be cytotoxic. Whether or not
other factors may mediate its internalization under special
conditions is not as yet known.
Placental ribonuclease inhibitor
Homology considerations have provided the opportunity to
examine the capacity of known inhibitors of pancreatic
RNase to inactivate angiogenin. Protein inhibitors of
pancreatic and other RNases have been identified in the
cytoplasm of a wide variety of mammalian tissues
(Blackburn et al., 1977). In particular, the human placental
inhibitor, PRI, has been purified and isolated: it very
effectively inhibits pancreatic RNase. PRI is also a potent
antagonist of both the angiogenic and ribonucleolytic
activities of angiogenin (Table III). In fact, it is almost 60
times more effective against angiogenin compared to RNase
and the stoichiometry of the interaction is 1:1. Analogous to
bovine pancreatic RNase, this inhibition is reversible, and
p-chloro- mercuribenzoate dissociates the complex readily
to yield active angiogenin, chromatographically identical to
the native protein. A slight molar excess of PRI suffices to
inhibit enzymatic activity completely (Shapiro & Vallee,
1987). Further, carboxymethylation of Lys-41 of pancreatic
RNase substantially reduces binding strength, indicating that
this residue is essential to the interaction between PRI and
RNase A (Lee, F.S., personal communication).
These findings represent a hitherto unsuspected function
for PRI: regulation of angiogenesis. This could lead to its
therapeutic use in the management of pathological
conditions characterized by or dependent on abnormal
neovascularization. Inhibition of both the biological and
enzymatic activities of angiogenin by human PRI may
therefore have important mechanistic, physiological and
pharmacologic implications.
In summary, the complete chemical characterization of a
unique human organogenic messenger molecule, ie, one that
induces organ formation, accomplishes a first major
objective in a long-term investigation of organogenesis in
general and angiogenesis in particular. The unexpected
homology to ribonuclease A allows the use of novel
approaches to the investigation of the biological process of
angiogenesis and may be relevant to the evolution of
organogenic molecules. Importantly, it provides a chemical
basis for the prediction of angiogenic function. These
provocative findings are thought to have important
physiological implications.
Table III Inhibition of angiogenin by human placental ribonuclease
inhibitor
Activity -PRI +PRI
RNA hydrolysisa 100 0
Angiogenesis, CAMb 57 16
Protein synthesis inhibitionc 100 0
'RNA (12 tg) was incubated with 0.8 iM angiogenin with or
without 0.96pM PRI at 37°C in 0.033 M HEPES, 0.033 MNaCl, pH
7.5 for 30 min. RNA hydrolysis (%) was determined by agarose gel
electrophoresis (Shapiro & Vallee, 1987). bAssays were performed
on the chick chorioallantoic membrane (CAM) as described (Fett et
al., 1985). Results (% positive) are the average of three separate
experiments with angiogenin concentrations of 75, 46 and 25ng,
respectively, with and without 2000, 700, and 180ng PRI,
respectively (Shapiro & Vallee, 1987). cProtein synthesis was carried
out in vitro using the rabbit reticulocyte lysate system. Angiogenin,
40nM, added to the lysate inhibited protein synthesis (100%).
Preincubation of angiogenin with an equimolar concentration of
PRI abolished the ability of angiogenin to inhibit protein synthesis
(St. Clair et al., 1987).
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